nach oben

Erschienen in:

01.10.2014

Increased levels of anti-heat-shock protein 60 (anti-Hsp60) indicate endothelial dysfunction, atherosclerosis and cardiovascular diseases in patients with mixed connective tissue disease

verfasst von: Edit Bodolay, Zoltan Prohászka, Gyorgy Paragh, Istvan Csipő, Gabor Nagy, Renata Laczik, Nora Demeter, Eva Zöld, Britt Nakken, Gyula Szegedi, Peter Szodoray

Erschienen in: Immunologic Research | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Heat-shock protein 60 (Hsp60) has been shown to provoke inflammation, and anti-Hsp60 may facilitate the development of atherosclerosis. In this study, we have investigated 30 patients with mixed connective tissue disease (MCTD) and assessed anti-Hsp60 and their relationship to cardiovascular diseases (CVD). Out of 30 patients with MCTD, 15 had CVDs. Anti-Hsp60 antibody was determined by enzyme-linked immunosorbent assay. Since endothelial dysfunction and accelerated atherosclerosis are characteristic to MCTD, a wide array of MCTD-, endothelial dysfunction- and CVD-associated parameters was investigated: serum lipid levels, paraoxonase activity (PON1), rich nuclear ribonucleoprotein U1 (anti-U1RNP), anti-endothelial cell antibodies, anti-cardiolipin and anti-β2-glycoprotein I antibody isotypes (anti-CL and anti-β2GPI), endothelin-1 (ET-1) levels, also intima–media thickness (IMT), a quantitative indicator of atherosclerosis. In MCTD, anti-Hsp60 antibody levels were significantly higher than in healthy individuals (p < 0.02). MCTD patients with CVD had significantly higher levels of anti-Hsp60 compared to MCTD without CVD (p = 0.001). Patients with MCTD had significantly lower high-density lipoprotein cholesterol (p = 0.02) and PON activity (p < 0.001), and significantly increased systolic (p < 0.0002) and diastolic (p < 0.001) blood pressure compared to healthy individuals. Anti-U1RNP levels (p < 0.002) and IMT were higher in patients compared to controls (p = 0.002). The CVD-positive MCTD patients had increased anti-Hsp60 (p < 0.0013), anti-CL IgG (p = 0.0005), ET-1 serum concentration (p < 0.05) and IMT levels (p < 0.001) compared to MCTD patients without CVD. Anti-Hsp60 showed a strong correlation with anti-oxLDL (r = 0.36, p = 0.01) and serum ET-1 (r = 0.62, p < 0.001) and negative correlation with PON activity (r = −0.47, p = 0.01). Anti-Hsp60 indicates endothelial injury, CVD, and can function as a novel atherosclerotic risk factor, also a valuable diagnostic marker in patients with MCTD.

Richter K, Haslbeck M, Buchner J. The heat shock response: life on the verge of death. Mol Cell. 2010;40:253–66.CrossRefPubMed

Wand-Wurtteberger A, Schoel B, Ivanyi J, Kaufmann SH. Surface expression by mononuclear phagocytes of an epitope shared with mycobacterial heat shock protein 60. Eur J Immunol. 1991;21:1089–92.CrossRef

Xu Q, Schett G, Seitz CS, Hu Y, Gupta RS, Wick G. Surface staining and cytotoxic activity of heat-shock protein 60 in stressed aortic endothelial cells. Circ Res. 1994;75:1078–85.CrossRefPubMed

Wick G, Henderson B, Knoflach M, et al. Atherosclerosis, autoimmunity to heat-shock proteins. In: Rose NR, Mackay IR, editors. The autoimmune diseases. 4th ed. Waltham: Academic Press; 2006. p. 889–97.CrossRef

Pershinka H, Wellenzohn B, Parson W, et al. Identification of atherosclerosis-associated conformational heat shock protein 60 epitopes by phage display and structural alignment. Atherosclerosis. 2007;194:79–87.CrossRef

Prohászka Z, Füst G. Immunological aspects of heat-shock proteins-the optimum stress of life. Mol Immunol. 2004;41:29–44.CrossRefPubMed

Mandal K, Jahangiri M, Xu Q. Autoimmunity to heat shock proteins in atherosclerosis. Autoimmun Rev. 2004;3:31–3.CrossRefPubMed

Alard J-E, Dueymes M, Youinou P, Jamin C. Modulation of endothelial cell damages by anti-Hsp60 autoantibodies in systemic autoimmune diseases. Autoimmun Rev. 2007;6:438–43.CrossRefPubMed

Perschinka H, Mayr M, Millonig G, et al. Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:1060–5.CrossRefPubMed

10.

Zhou X, Hansson G. Vaccination and atherosclerosis. Curr Atheroscler Rep. 2004;6:158–64.CrossRefPubMed

11.

Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease- an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52:148–59.CrossRefPubMed

12.

Hoffmann RW, Cassidy JT, Takeda Y, Smith-Jones EL, Wang GS, Sharp GC. U1-70 kD autoantibody positive connective tissue disease in children: a longitudinal clinical and serological analysis. Arthritis Rheum. 1993;36:1599–602.CrossRef

13.

Maldonado ME, Perez M, Pignac-Kobinger J, Marx ET, Tozman EM, Greidinger EL, et al. Clinical and Immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian population. J Rheumatol. 2008;35:1–9.

14.

Hoffman RW, Maldonado ME. Immune pathogenesis of mixed connective tissue disease: a short analytical review. Clin Immunol. 2008;128:8–17.CrossRefPubMed

15.

Bodolay E, Szekanecz Z, Dévényi K, Galuska L, Csipő I, Végh J, et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology. 2005;44:656–61.CrossRefPubMed

16.

Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2012;26:61–72.CrossRefPubMed

17.

Gunnarsson R, Molberg O, Gilboe I, Gran JT. The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. PAHNOR1 study group. Ann Rheum Dis. 2011;70:1047–51.CrossRefPubMed

18.

Hasegawa EM, Caleiro MT, Fuller R, Carvalho JF. The frequency of anti-beta2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease. Lupus. 2009;18:618–21.CrossRefPubMed

19.

Hajas A, Sandor J, Csathy L, Csipo I, Barath S, Paragh G, Seres I, Szegedi G, Shoenfeld Y, Bodolay E. Vitamin D insufficiency in a large MCTD population. Autoimmun Rev. 2011;10:317–24.CrossRefPubMed

20.

Szodoray P, Hajas A, Kardos L, Dezso B, Soos G, Zold E, Vegh J, Csipo I, Nakken B, Zeher M, Szegedi G, Bodolay E. Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus. 2012;21:1412–22.CrossRefPubMed

21.

Bodolay E, Csípő I, Gál I, Sipka S, Gyimesi E, Szekanecz Z, et al. Anti-endothel cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms. Clin Exp Rheumatol. 2004;22:409–15.PubMed

22.

Bodolay E, Seres I, Szodoray P, Csipő I, Jakab Z, Végh J, Szilágyi A, Szegedi G, Paragh G. The evaluation of paraoxonase (PON) activity in patients with mixed connective tissue disease. J Rheumatol. 2008;35:237–43.PubMed

23.

Alarcon-Segovia D, Villarreal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and anti-nuclear antibodies. Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division); 1987. p. 33–40.

24.

Horváth L, Cervenak L, Oroszlán M, Prohászka Z, Uray K, Hudecz F, Baranyi E, Madácsy L, Singh M, Romics L, Füst G, Pánczél P. Antibodies against different epitopes of heat-shock protein 60 in children with type 1 diabetes mellitus. Immunol Lett. 2002;80:155–62.CrossRefPubMed

25.

Prohászka Z, Daha MR, Süsal C, Daniel V, Szlávik J, Bánhegyi D, Nagy K, Várkonyi V, Horváth A, Ujhelyi E, Tóth FD, Uray K, Hudecz F, Füst G. C1q autoantibodies in HIV infection: correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins. Clin Immunol. 1999;90:247–55.CrossRefPubMed

26.

Soltesz P, Der H, Veres K, Laczik R, Sipka S, Szegedi G, Szodoray P. Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. Rheumatology. 2008;47:1628–34.CrossRefPubMed

27.

Kerekes G, Soltész P, Nurmohamed MT, Gonzalez-Gay MA, Turiel M, Végh E, Shoenfeld Y, McInnes I, Szekanecz Z. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol. 2012;8:224–34.CrossRefPubMed

28.

Mackness M, Mackness B. Targeting paraoxonase-1 in atherosclerosis. Expert Opin Ther Targets. 2013;17:829–37.CrossRefPubMed

29.

Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci. 2012;4:523–32.PubMedCentralCrossRefPubMed

30.

Khan IU, Wallin R, Gupta RS, Kammer GM. Protein kinase A-catalized phosphorylation of heat shock protein 60 chaperone regulates its attachment to histone 2B in the T lymphocyte plasma membrane. Proc Natl Acad Sci USA. 1998;95:10425–30.PubMedCentralCrossRefPubMed

31.

Schett G, Metzler B, Kleindienst R, Amberger A, Recheis H, Xu Q, Wick G. Myocardial injury leads to a release of heat shock protein (hsp) 60 and a suppression of the anti-hsp65 immune response. Cardiovasc Res. 1999;42:685–95.CrossRefPubMed

32.

Hochleitner B-W, Hochleitner E-O, Obrist P, Eberl T, Amberger A, Xu Q, Margreiter R, Wick G. Fluid shear stress induces heat shock protein 60 expression in endothelial cells in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2000;20:617–23.CrossRefPubMed

33.

Xu Q, Kleindienest R, Schnett G, et al. Regression of arteriosclerotic lesions induced by immunization with heat shock protein 65-containing material in normocholesterolemic, but not hypercholesterolemic, rabbits. Atherosclerosis. 1996;123:145–55.CrossRefPubMed

34.

Xu Q, Leuf G, Weimann S, Gupta RS, Wolf H, Wick G. Staining of endothelial cells and macrophages in atherosclerotic lesions with human heat-shock protein-reactive antisera. Arterioscler Thromb. 1993;13:1763–9.CrossRefPubMed

35.

Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, Stulnig T, Luef G, Wick G. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet. 1993;341:255–9.CrossRefPubMed

36.

Xu Q, Schett G, Perschinka H, Mayr M, Egger G, Oberhollenzer F, Willeit J, Kiechl S, Wick G. Serum soluble heat sock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation. 2000;102:14–20.CrossRefPubMed

37.

Burian K, Kis Z, Virok D, et al. Independent and join effects of antibodies to human heat-shock protein 60 and Chlamydia pneumonia infection in the development of coronary atherosclerosis. Circulation. 2001;103:1503–8.CrossRefPubMed

38.

Zhu J, Quyyumi AA, Rott D, et al. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation. 2001;103:1071–5.CrossRefPubMed

39.

Laczik R, Szodoray P, Veres K, Szomják E, Csipő I, Sipka S, Shoenfeld Y, Szekanecz Z, Soltész P. Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus. 2011;20:730–5.CrossRefPubMed

40.

Charach G, Rabinovich A, Argov O, Weintraub M, Charach L, Ayzenberg O, George J. Anti-oxidized low-density lipoprotein antibodies in chronic heart failure. World J Cardiol. 2012;4:302–8.PubMedCentralCrossRefPubMed

41.

Puurunen M, Mantarri M, Manninen V, Tenkanen L, Algthan G, Ehnholm C, Vaarala O, Aho K, Palosuo T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med. 1994;154:2605–9.CrossRefPubMed

42.

Tsutsui T, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Ohnishi M, Kinoshita M. Plasma oxidized low density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol. 2002;39:957–62.CrossRefPubMed

43.

Sherer Y, Cerinic MM, Bartoli F, Blagojevic J, Conforti ML, Gilburd B, Ehrenfeld M, Shoenfeld Y. Early atherosclerosis and autoantibodies to heat-shock proteins and oxidized LDL in systemic sclerosis. Ann N Y Acad Sci. 2007;1108:259–67.CrossRefPubMed

44.

Hoppichler F, Koch T, Dzien A, Gschwandtner G, Lechleitner M. Prognostic value of antibody titre to heat-shock protein 65 on cardiovascular events. Cardiology. 2000;94:220–3.CrossRefPubMed

45.

Giannessi D, Colotti C, Maltinti M, Del Ry S, Prontera C, Turchi S, Labbate A, Neglia D. Circulating heat shock protein and inflammatory markers in patients with idiopathic left ventricular dysfunction: their relationships with myocardial and microvascular impairment. Cell Stress Chaperones. 2007;12:265–74.PubMedCentralCrossRefPubMed

46.

Pockley AG, De Faire U, Kiessling R, Lemne C, Thulin T, Frostegard J. Circulating heat shock protein and heat shock protein antibody levels in established hypertension. J Hypertens. 2002;20:1815–20.CrossRefPubMed

47.

Okawa-Takatsuji M, Aotsuka S, Uwatoko S, Takaono M, Iwasaki K, Kinoshita M, Sumiya M. Endothelial cell-binding activity of anti-U1-ribonucleoprotein antibodies in patients with connective tissue diseases. Clin Exp Immunol. 2001;126:345–54.PubMedCentralCrossRefPubMed

48.

Greidinger EL, Zang Y, Jaimes K, Hogenmiller S, Nassiri M, Bejarano P, Barber GN, Hoffman RW. A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen. Arthritis Rheum. 2006;54:661–9.CrossRefPubMed

49.

Vegh J, Szodoray P, Kappelmayer J, Csipő I, Udvardy M, Lakos G, et al. Clinical and imunoserological characteristics of mixed connective tissue disease (MCTD) associated with pulmonary arterial hypertension (PAH). Scand J Rheumatol. 2006;64:69–76.

50.

Jones DB, Coulson AFW, Duff GW. Sequence homologies between hsp60 and autoantigens. Immunol Today. 1993;14:115–8.CrossRefPubMed

51.

Portig I, Pankuweit S, Maisch B. Antibodies against stress proteins in sera of patents with dilated cardiomyopathy. J Mol Cell Cardiol. 1997;29:2245–51.CrossRefPubMed

Titel: Increased levels of anti-heat-shock protein 60 (anti-Hsp60) indicate endothelial dysfunction, atherosclerosis and cardiovascular diseases in patients with mixed connective tissue disease
verfasst von: Edit Bodolay
Zoltan Prohászka
Gyorgy Paragh
Istvan Csipő
Gabor Nagy
Renata Laczik
Nora Demeter
Eva Zöld
Britt Nakken
Gyula Szegedi
Peter Szodoray
Publikationsdatum: 01.10.2014
Verlag: Springer US
Erschienen in: Immunologic Research / Ausgabe 1/2014
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-014-8552-x

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Increased levels of anti-heat-shock protein 60 (anti-Hsp60) indicate endothelial dysfunction, atherosclerosis and cardiovascular diseases in patients with mixed connective tissue disease

Abstract

Neu im Fachgebiet HNO

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Defective functions of polymorphonuclear neutrophils in patients with common variable immunodeficiency

An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia

The combined loss of Gads and CD127 reveals a novel function of Gads prior to TCRβ expression

Built-in adjuvanticity of genetically and protein-engineered chimeric molecules for targeting of influenza A peptide epitopes

Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment, and discovery

Expression, cloning, and IgE-binding of the full-length dust mite allergen Der f 8

Neu im Fachgebiet HNO

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

Update HNO